ACELRX PHARMACEUTICALS INC Business Finance Contracts & Agreements
63 Contracts & Agreements
- Assignment Agreements (2 contracts)
- Loan Agreements (9)
- Purchase Agreements (13)
- Registration Rights Agreements (3)
- Stock Agreements (10)
- Trust Agreements (1)
- Underwriting Agreements (3)
- Warrant Agreements (22)
- Form of Amendment No. 1 to Securities Purchase Agreement, dated September 30, 2024, by and among Talphera, Inc. and entities affiliated with Nantahala Management, LLC (Filed With SEC on October 1, 2024)
- Amended and Restated 2011 Employee Stock Purchase Plan (Filed With SEC on June 24, 2024)
- Payment Interest Purchase Agreement between the Registrant and XOMA (US) LLC, dated as of January 12, 2024 (Filed With SEC on May 14, 2024)
- Form of Pre-Funded Warrant (January 2024) (Filed With SEC on January 22, 2024)
- Form of Registration Rights Agreement, dated January 17, 2024, by and among Talphera, Inc. and the Purchasers (Filed With SEC on January 22, 2024)
- Form of Securities Purchase Agreement, dated January 17, 2024 by and among Talphera, Inc. and Investor Company ITF Rosalind Master Fund L.P (Filed With SEC on January 22, 2024)
- Form of Securities Purchase Agreement, dated January 17, 2024, by and among Talphera, Inc. and entities affiliated with Nantahala Management, LLC (Filed With SEC on January 22, 2024)
- Asset Purchase Agreement, between the Registrant and Vertical Pharmaceuticals, LLC, dated March 12, 2023 (Filed With SEC on November 14, 2023)
- Form of placement agent Series B common stock warrant (Filed With SEC on July 21, 2023)
- Form of placement agent Series A common stock warrant (Filed With SEC on July 21, 2023)
- Form of Pre-Funded Warrant (July 2023) (Filed With SEC on July 21, 2023)
- Form of Series B common stock warrant (July 2023) (Filed With SEC on July 21, 2023)
- Form of Series A common stock warrant (July 2023) (Filed With SEC on July 21, 2023)
- Form of Registration Rights Agreement, dated July 17, 2023, by and between AcelRx Pharmaceuticals, Inc. and the Purchasers (Filed With SEC on July 21, 2023)
- Form of Securities Purchase Agreement, dated July 17, 2023, by and between AcelRx Pharmaceuticals, Inc. and the Purchasers (Filed With SEC on July 21, 2023)
- Form of Securities Purchase Agreement, dated December 27, 2022 (Filed With SEC on December 29, 2022)
- Form of Common Warrant, as amended (November 2021) (Filed With SEC on December 29, 2022)
- Form of Pre-Funded Warrant (December 2022) (Filed With SEC on December 29, 2022)
- Form of Common Warrant (December 2022) (Filed With SEC on December 29, 2022)
- Registration Rights Agreement, dated August 3, 2022, between AcelRx Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 4, 2022)
- Securities Purchase Agreement, dated August 3, 2022, between AcelRx Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 4, 2022)
- Common Stock Purchase Warrant, dated August 3, 2022 (Filed With SEC on August 4, 2022)
- Second Amendment to Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of November 14, 2021 (Filed With SEC on March 10, 2022)
- Contingent Value Rights Agreement, dated as of January7, 2022, by and among AcelRx Pharmaceuticals, Inc., James Wilkie, solely in his capacity as the representative of the Lowell... (Filed With SEC on January 12, 2022)
- Purchase Agreement between the Company and the Purchasers, dated November 15, 2021 (Filed With SEC on November 15, 2021)
- Form of Warrant (Filed With SEC on November 15, 2021)
- First Amendment to Loan and Security Agreement, dated as of May 5, 2021, between Oxford Finance, LLC and the Registrant (Filed With SEC on November 15, 2021)
- Description of Capital Stock (Filed With SEC on March 15, 2021)
- Underwriting Agreement (Filed With SEC on January 21, 2021)
- Purchase Agreement between the Company and the Purchasers, dated July 22, 2020 (Filed With SEC on July 23, 2020)
- Description of Capital Stock (Filed With SEC on March 16, 2020)
- Loan and Security Agreement with Oxford Finance LLC, dated as of May 30, 2019 (Filed With SEC on June 3, 2019)
- Form of Warrant to Purchase Common Stock of the Registrant, dated as of May 30, 2019 (Filed With SEC on June 3, 2019)
- Underwriting Agreement, dated as of November 9, 2018, by and among AcelRx Pharmaceuticals, Inc., Credit Suisse Securities (USA) LLC and Jefferies LLC (Filed With SEC on November 13, 2018)
- Underwriting Agreement, dated as of July 12, 2018, by and between AcelRx Pharmaceuticals, Inc. and Cantor Fitzgerald & Co (Filed With SEC on July 13, 2018)
- amended and restated LOAN AND SECURITY AGREEMENT (Filed With SEC on March 3, 2017)
- AMENDMENT NO. 3 TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (Filed With SEC on November 2, 2016)
- WARRANT MODIFICATION AGREEMENT (Filed With SEC on November 2, 2016)
- WARRANT MODIFICATION AGREEMENT (Filed With SEC on November 2, 2016)
- AcelRx Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on June 21, 2016)
